Skip to main content

Table 3 Readiness to Perform Visual Analogue Scale

From: Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance

Questions

Treatment

Time (h)

p-level

Pre

1

2

I am looking forward to today’s workout

PLA

3.67 ± 0.85

3.61 ± 1.00

3.61 ± 0.87

0.21

PWS

3.71 ± 0.77

3.89 ± 0.79

3.65 ± 0.65

PWS + S

3.71 ± 0.99

3.82 ± 1.17

3.51 ± 1.09

I am optimistic about my future performance

PLA

3.74 ± 0.83

3.70 ± 0.94

3.78 ± 0.88

0.02q

PWS

3.88 ± 0.69

4.05 ± 0.73 a

3.83 ± 0.70

PWS + S

4.00 ± 0.69

4.21 ± 0.62 a

4.01 ± 0.71

I feel vigorous and energetic

PLA

3.23 ± 0.95

3.35 ± 0.90

3.38 ± 1.04

0.001

PWS

3.19 ± 0.89

3.77 ± 0.78 *a

3.33 ± 1.09

PWS + S

3.33 ± 0.77

3.89 ± 0.73 *a

2.96 ± 0.97 a,b

I have little muscle soreness

PLA

3.60 ± 0.99

3.42 ± 0.99

3.29 ± 1.01

0.17

PWS

3.54 ± 1.17

3.81 ± 1.35

3.25 ± 1.03

PWS + S

3.13 ± 1.31

3.27 ± 1.28

3.21 ± 1.12

  1. Values are means ± standard deviations. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.03), time (p = 0.01), and treatment x time (p = 0.004). Greenhouse-Geisser linear or quadratic (q) univariate p-levels of interactions (treatment x time) are reported above * represents p < 0.05 difference from baseline. a denotes a significant difference from PLA. b denotes a significant difference from PWS. c denotes a significant difference from PWS + S